Physician profile
Hamish Patel
NPI 1689023228
$4,891.14
in general payments reported to CMS, 2019-2025
27 companies · $20.00 in 2025
The $20.00 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $1,147 · 2021: $1,087 · 2022: $1,539 · 2023: $16.41 · 2024: $65.76 · 2025: $20.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $82.17 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $82.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $927.29 | 2020-2024 | Fasenra |
| Glaxosmithkline, LLC. | $499.89 | 2019-2021 | |
| Cook Incorporated | $473.37 | 2022 | |
| Inari Medical, INC. | $432.38 | 2022 | |
| Amgen INC. | $307.47 | 2019-2022 | |
| Cook Medical LLC | $261.01 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $245.45 | 2019-2020 | |
| Abiomed | $212.47 | 2020-2021 | |
| Pulmonx Corporation | $146.87 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $138.96 | 2020-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2019 | |
| Portola Pharmaceuticals, LLC | $124.82 | 2020 | |
| Csl Behring | $124.44 | 2019 | |
| Genzyme Corporation | $121.36 | 2020 | |
| Merck Sharp & Dohme LLC | $114.45 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $114.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.95 | 2020-2021 | |
| Novo Nordisk INC | $97.96 | 2022 | |
| Ekos Corporation | $96.50 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $52.64 | 2021 | |
| Advanced Respiratory, INC | $34.75 | 2020 | |
| Phadia US INC. | $28.84 | 2021 | |
| Pharmacosmos Therapeutics INC. | $28.62 | 2024 | Monoferric |
| Eko Health, INC. | $20.00 | 2025 | |
| Edwards Lifesciences Corporation | $19.25 | 2019 | |
| Genentech USA, INC. | $19.19 | 2024 | Ocrevus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.